270 related articles for article (PubMed ID: 35267028)
1. Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia.
Thuret I; Ruggeri A; Angelucci E; Chabannon C
Stem Cells Transl Med; 2022 Apr; 11(4):407-414. PubMed ID: 35267028
[TBL] [Abstract][Full Text] [Related]
2. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
3. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.
Marktel S; Scaramuzza S; Cicalese MP; Giglio F; Galimberti S; Lidonnici MR; Calbi V; Assanelli A; Bernardo ME; Rossi C; Calabria A; Milani R; Gattillo S; Benedicenti F; Spinozzi G; Aprile A; Bergami A; Casiraghi M; Consiglieri G; Masera N; D'Angelo E; Mirra N; Origa R; Tartaglione I; Perrotta S; Winter R; Coppola M; Viarengo G; Santoleri L; Graziadei G; Gabaldo M; Valsecchi MG; Montini E; Naldini L; Cappellini MD; Ciceri F; Aiuti A; Ferrari G
Nat Med; 2019 Feb; 25(2):234-241. PubMed ID: 30664781
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
[TBL] [Abstract][Full Text] [Related]
6. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy.
Srivastava A; Shaji RV
Haematologica; 2017 Feb; 102(2):214-223. PubMed ID: 27909215
[TBL] [Abstract][Full Text] [Related]
7. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F; Lang P; Wall D; Meisel R; Corbacioglu S; Li AM; de la Fuente J; Shah AJ; Carpenter B; Kwiatkowski JL; Mapara M; Liem RI; Cappellini MD; Algeri M; Kattamis A; Sheth S; Grupp S; Handgretinger R; Kohli P; Shi D; Ross L; Bobruff Y; Simard C; Zhang L; Morrow PK; Hobbs WE; Frangoul H;
N Engl J Med; 2024 May; 390(18):1663-1676. PubMed ID: 38657265
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy and Genome Editing.
Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
[TBL] [Abstract][Full Text] [Related]
9. Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients.
Ouyang W; Dong G; Zhao W; Li J; Zhou Z; Yang G; Liu R; Li Y; Zhang Q; Du X; Sun H; Gu Y; Lai Y; Liu S; Liu C
Hum Gene Ther; 2021 May; 32(9-10):481-494. PubMed ID: 33256481
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin gene therapy for β-thalassemia.
Bank A
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1187-201. PubMed ID: 21075288
[TBL] [Abstract][Full Text] [Related]
11. Decision-making about gene therapy in transfusion dependent thalassemia.
Quarmyne MO; Ross D; Sinha C; Bakshi N; Boudreaux J; Krishnamurti L
BMC Pediatr; 2022 Sep; 22(1):536. PubMed ID: 36085025
[TBL] [Abstract][Full Text] [Related]
12. Defining curative endpoints for transfusion-dependent β-thalassemia in the era of gene therapy and gene editing.
Corbacioglu S; Frangoul H; Locatelli F; Hobbs W; Walters M
Am J Hematol; 2024 Mar; 99(3):422-429. PubMed ID: 38100154
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β
Fu B; Liao J; Chen S; Li W; Wang Q; Hu J; Yang F; Hsiao S; Jiang Y; Wang L; Chen F; Zhang Y; Wang X; Li D; Liu M; Wu Y
Nat Med; 2022 Aug; 28(8):1573-1580. PubMed ID: 35922667
[TBL] [Abstract][Full Text] [Related]
14. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
15. Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.
Eckrich MJ; Frangoul H
Semin Hematol; 2023 Jan; 60(1):3-9. PubMed ID: 37080708
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
Segura EER; Ayoub PG; Hart KL; Kohn DB
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
[TBL] [Abstract][Full Text] [Related]
17. An Expert Overview on Therapies in Non-Transfusion-Dependent Thalassemia: Classical to Cutting Edge in Treatment.
Saeidnia M; Fazeli P; Farzi A; Atefy Nezhad M; Shabani-Borujeni M; Erfani M; Tamaddon G; Karimi M
Hemoglobin; 2023 Nov; 47(2):56-70. PubMed ID: 37325871
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for homozygous beta-thalassemia. Is it a reality?
Boulad F; Rivière I; Sadelain M
Hemoglobin; 2009; 33 Suppl 1():S188-96. PubMed ID: 20001625
[TBL] [Abstract][Full Text] [Related]
19. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
20. A New Era for Hemoglobinopathies: More Than One Curative Option.
Psatha N; Papayanni PG; Yannaki E
Curr Gene Ther; 2017; 17(5):364-378. PubMed ID: 29357790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]